Diet and Hereditary Haemorrhagic Telangiectasia
NCT01692015 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2024-03-29
Summary
Hereditary Haemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people. The purpose of this study is to provide data regarding the diet and nosebleed frequency using a questionnaire.
This will be filled in by people with HHT.
The questionnaire has been designed in paper format.
Conditions
- Hereditary Haemorrhagic Telangiectasia (HHT)
Interventions
- OTHER
-
Questionnaire on dietary history
- OTHER
-
Questionnaire on nosebleed severity
- OTHER
-
One week food diary generated by weighing foods
- PROCEDURE
-
Blood tests for full blood count, albumin, and indices of nutritional status
Sponsors & Collaborators
-
Imperial College London
lead OTHER
Principal Investigators
-
Claire L Shovlin, PhD FRCP · Imperial College London
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-04-30
- Primary Completion
- 2013-09-30
- Completion
- 2016-09-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Studies of White Blood Cells Derived From HHT Patients
NCT00230633 ·Status: ACTIVE_NOT_RECRUITING
-
Hemochromatosis--Genetic Prevalence and Penetrance
NCT00006312 ·Status: COMPLETED
-
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
NCT01398644 ·Status: UNKNOWN ·Phase: PHASE3
-
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension
NCT04086537 ·Status: COMPLETED
-
Investigation of the Frequency of Hereditary Hyper Alpha-tryptasemia in Patients With Elevated Basal Tryptasemia
NCT06133907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis
NCT00440986 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Erythrocyte Apheresis Versus Phlebotomy in Hemochromatosis
NCT00509652 ·Status: UNKNOWN ·Phase: NA
-
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
NCT01810965 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
NCT05506358 ·Status: COMPLETED ·Phase: NA
-
Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?
NCT00502398 ·Status: UNKNOWN
-
Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria
NCT00004398 ·Status: COMPLETED ·Phase: PHASE1
-
Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter
NCT00481221 ·Status: UNKNOWN
-
Iron Profile in Patients With Congenital Cyanotic Heart Disease
NCT04104061 ·Status: UNKNOWN
-
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
NCT00004397 ·Status: COMPLETED ·Phase: PHASE1
-
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
NCT00230165 ·Status: RECRUITING
-
Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients
NCT07055503 ·Status: ENROLLING_BY_INVITATION
-
Detection Of β-thalassemia Carriers In Assiut
NCT03822585 ·Status: UNKNOWN ·Phase: NA
-
Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
NCT01496963 ·Status: COMPLETED
-
Hereditary Spherocytosis and Vascular Function
NCT04451785 ·Status: COMPLETED ·Phase: NA
-
Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
NCT01294891 ·Status: COMPLETED
-
Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia
NCT02526121 ·Status: COMPLETED ·Phase: NA
-
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
NCT00389935 ·Status: COMPLETED ·Phase: PHASE2
-
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
NCT05864170 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
NCT01631708 ·Status: COMPLETED ·Phase: NA
-
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
NCT01239901 ·Status: COMPLETED